HC11- Clinical radiotherapy Flashcards
treatment cancer
surgery - radiotherapy - chemotherapy - immunotherapy
clinical factors radiotherapy (6)
- tumor size
- localization
- primary tumor
- metastases
- histology
- fitness patient
radiosensitivity > very sensitive
lymphoma, seminoma, small cell lung cancer
dosage very sensitive > microscopic
20-40 Gy
dosage very sensitive > macroscopic
30-60 Gy
radiosensitivity > average sensitivity
carcinoma
dosage average sensitivity > microscopic
40-60 Gy
dosage average sensitivity > macroscopic
60-80 Gy
radiosensitivity > not sensitive
sarcoma, glioblastoma, melanoma
dosage not sensitive > microscopic
60-80 Gy
dosage not sensitive > macroscopic
> 80 Gy
tissue sensitivity
- bone marrow
- hair
- brain
- lungs
- spinal cord
- kidneys
- small intestine
- skin
- bone marrow = 8 Gy
- hair = 10 Gy
- brain = 30-60 Gy
- lungs = 20-40 Gy
- spinal cord = 50-60 Gy
- kidneys = 15-20 Gy
- small intestine = 40-70 Gy
- skin = 70-80 Gy
challenge radiotherapy
killing the tumor without killing the patient
treatment recurring mammacarcinoma
hyperthermia and reirradiation
hyperthermia > WIRA
water-filtered infrared A > 434 MHz probe
advantages hyperthermia
allows for significant reductions in re-RT dose
bladder cancer not invading muscle
- 70% of cases
- Ta-T1-cis, high
bladder cancer invading muscle
- 30% of cases
- T2-T4
- survival =24 months
treatment bladder cancer (2)
- External Beam Radiation Therapy (EBRT)
- Barchytherapy
PSA
Prostate Specific Antigen
Gleason score (1-5 tumor differentiation)
first = most dominant differentiation, second = second most dominant differentiation
treatment options (3)
- active surveillance
- curative
- pallative
curative treatment (2)
- surgery
- radiotherapy > + hormone therapy
pallative treatment (3)
- hormone therapy
- chemotherapy
- radiotherapy
Brachytherapy I-125
- for local tumors, low stage
- advantage > high dose locally = 144 Gy, low dose in healthy tissue, one time
- disadvantage > permanent, operation
